Study | Adverse events |
---|---|
Bodes-Pardo et al. [51] | Not reported |
Chaibi et al. [52] | No severe or serious adverse effects |
Dunning et al. [53] | No severe or serious adverse effects |
Esin et al. [54] | Not reported |
Haas et al. [55] | Not reported |
Haas et al. [56] | No severe or serious adverse effects |
Hall et al. [57] | Not reported |
Jafari et al. [58] | Not reported |
Jull et al. [59] | No severe or serious adverse effects. 6.7% of total headaches experienced by participants during the trial were reported to be caused by the treatment |
Malo-Urriès et al. [60] | No severe or serious adverse effects |
Nilsson et al. [61] | Not reported |
Sedighi et al. [62] | Not reported |
Sharma et al. [63] | Not reported |
von Piekartz et al. [64] | No severe or serious adverse effects. 3 patients dropped out after the second follow up due to worsening of their symptoms |
Yang and Kang [65] | Not reported |
Youssef and Shanb [66] | Not reported |
Abdel et al. [67] | Not reported |
Dunning et al. [68] | No severe or serious adverse effects. 60% of participants in the dry needling group experienced localized soreness, and 24% localized ecchymosis, resolved withing 48Â h. 4% experienced drowsiness or nausea, resolved within several hours |
Lerner-Lentz et al. [69] | Not reported |
Moustafa et al. [70] | No severe or serious adverse effects |